Vitiligo: Current Therapies and Future Treatments.

Authors:
Seneschal J; Boniface K.

Journal:
Dermatol Pract Concept

Publication Year: 2023

DOI:
10.5826/dpc.1304S2a313S

PMCID:
PMC10824325

PMID:
38241396

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Dermatol Pract Concept

Abbreviation: Dermatol Pract Concept

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Dermatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A Case Series of Scurvy Presenting as Bruising.
Quigley C; Yhoo H; Victory L and 3 more (2024) - Transparency Score: 3/6
A Comparison of Clinical, Demographic and Treatment Characteristics of Pediatric-Onset and Adult-On…
Akbaş A; Kılınç F; Hayran Y. (2024) - Transparency Score: 3/6
An Unusual Case of Lichen Striatus Onset Under Dupilumab in a Patient With Alopecia Areata.
Tancredi V; Babino G; Fulgione E and 2 more (2024) - Transparency Score: 3/6
A Rare Case of Angiolymphoid Hyperplasia With Eosinophilia: A Dermoscopic and Therapeutic Teaching …
Chessa MA; Maltoni L; Robuffo S and 3 more (2024) - Transparency Score: 3/6
A Rare Case of Follicular Porokeratosis Ptychotropica: When Dermoscopy Enghlitens Clinics.
El Imene Ouni N; Mokni S; Fetoui NG and 8 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing Interests: Julien Seneschal: received grants and/or honoraria from AbbVie, Bristol Myers Squibb, Calypso Biotech, Eli Lilly, Incyte, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Sanofi, Sun Pharmaceuticals, and Viela Bio; and has a patent on MMP9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder and three-dimensional model of depigmenting disorder. Katia Boniface: received grants from Calypso Biotech, LEO Pharma, Pfizer, Pierre Fabre, Sanofi, and has a patent on MMP9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder and three-dimensional model of depigmenting disorder."

Evidence found in paper:

"Funding: None."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025